ERBB2 and cancer: Additionally, there is a lack of comprehensive data for accurately calculating residual cancer burden, and most HER2-positive patients did not receive the current standard of care—including targeted therapies such as trastuzumab—at the time of recruitment, limits our ability to fully assess molecular characteristics related to chemosensitivity in this subgroup.